Pharmafile Logo

News and Press Releases

Agreement to Explore Optimer Vehicles for Targeted Delivery of siRNA

New Collaboration to Evaluate Aptamer's Fibrotic Liver Delivery Vehicles with siRNA 3 July 2024, York, England - Aptamer Group plc (AIM: APTA), the developer of novel Optimer binders to enable...

Category: Drug Delivery
Posted: July 3, 2024

Aptamer Group
info@aptamergroup.co.uk
Aptamer group, Suite 2.80 – 2.87, Bio Centre, Innovation Way, Heslington, York, YO10 5NY

FDA and CluePoints Sign New 3 Year Cooperative Research and Development Agreement to Assess Data Quality using Statistical Modelling and Machine Learning

FDA extends its use of CluePoints to include AI/ML within an automated system to assess data quality in multicenter clinical trials 5 June 2024 -- Pennsylvania, US -- CluePoints, providers...

Category: Biotechnology, Pharmaceutical
Posted: June 5, 2024

CluePoints
contact@cluepoints.com
1000 Continental Drive, Suite 240, King of Prussia, PA 19406

Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024

Biogen
Biogen International GmbH Neuhofstrasse 30 6340 Baar Switzerland

TMC Pharma champions holistic approach to medical services in rare disease drug development

13 March 2024 – In a recent webinar, rare disease specialist and global clinical research organisation (CRO) TMC Pharma gathered esteemed speakers to share insights into the scope of medical...

Category: Drug Discovery, Pharmaceutical
Posted: March 13, 2024

TMC Pharma
info@tmcpharma.com
Lodge Farm Barn Elvetham Park Estate, Fleet Road, Hartley Wintney, Hampshire RG27 8AS, UK

Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by US Food and Drug Administration

Compound is currently undergoing clinical trials as a potential treatment option for patients with RET altered tumours 5 March 2024 -- London, UK -- Ellipses Pharma, a global drug development...

Category: Drug Discovery
Posted: March 5, 2024

Ellipses Pharma
enquiries@ellipses.life
10 STRATTON STREET W1J 8LG LONDON

Clinigen launches ‘What is Possible?’ campaign to accelerate access to medicines on Rare Disease Day 

With over 7,000 rare diseases that impact over 300 million people globally, just 5% of rare diseases have a licensed treatment 29 February 2024 -- London, UK -- Clinigen, the...

Category: Other
Posted: February 29, 2024

Clinigen
25 Bedford Square Bloomsbury London WC1B 3HH

CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA

Six-year collaboration recognised at prestigious awards ceremony for its continued success in advancing OOC research to support widespread adoption across the pharmaceutical industry 23 November 2023 -- Cambridge, UK --...

Category: Clinical Trials
Posted: November 23, 2023

CN-Bio
enquiries@cn-bio.com
30 Upper High Street, Thame, Oxfordshire, OX9 3EZ

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care

The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science 18 October 2023 -- Boston, US and Rolle, Switzerland --...

Category: Biotechnology
Posted: October 19, 2023

SOPHiA Genetics
La Pièce 12, CH-1180 Rolle, Switzerland

AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023

Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...

Category: Clinical Trials
Posted: October 12, 2023

AstraZeneca
Medical.InformationUK@astrazeneca.com
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

Signum Surgical Completes Clinical Trial for BioHealx

Galway based company compiling data for submission of a De Novo classification request to US FDA Novel surgical option for the treatment of anal fistula, a painful and debilitating colorectal...

Category: Clinical Trials
Posted: September 12, 2023

Signum Surgical
INFO@SIGNUMSURGICAL.COM
NEW DOCKS, THE DOCKS, GALWAY